Feasibility of Neoadjuvant Immune Checkpoint Blockade for Resectable Diffuse Pleural Mesothelioma Along Potential of ctDNA Analyses to Detect Residual Disease By Ogkologos - September 22, 2025 88 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase II study Source RELATED ARTICLESMORE FROM AUTHOR Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for Patients with Cervical Cancer and Intermediate Pathologic Risk Factors Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer MOST POPULAR Nivolumab Injections Could Make Treatment Easier for More People with Cancer March 13, 2024 Making Transformative Advances against Childhood Cancer: A Conversation with Dr. Doug... September 28, 2022 More Evidence that Ruxolitinib Benefits Some Patients with Graft-Versus-Host Disease May 29, 2020 DIY Mosquito Traps & Deterrents (That Really Work) June 23, 2021 Load more HOT NEWS Excellence in cancer research nursing: Celebrating innovation during tough times Piecing together the puzzle: Antibiotics, the microbiome and bowel cancer Innovative cancer spinouts: 3 new projects get green light Sharing Energy
